A Phase 1/2, Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia

Trial Profile

A Phase 1/2, Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Staphylococcal-protein-A (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Therapeutic Use
  • Sponsors Protalex
  • Most Recent Events

    • 26 Oct 2017 According to a Protalex media release, results from the higher dose cohorts are anticipated in coming months.
    • 01 Aug 2017 According to a Protalex media release, data Analysis of Second Dose Cohort has been completed, and following this analysis Treatment of the first patient in the third cohort at a dose of 6.0 micrograms/kg, double that of the second dose cohort of 3.0 micrograms/kg, is expected soon.
    • 26 Apr 2017 Planned End Date changed from 1 Sep 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top